V

    Viking Therapeutics Inc (VKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $32.78
    +0.62 (+1.93%)

    Market Cap: $3.75B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -1.15%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.07
    Range$-1.38 - $-0.66
    16 analysts
    EPS Revisions
    5
    0
    7d
    5
    3
    30d
    EPS Estimate Drift
    90d ago$-1.11-4.2%
    60d ago$-1.10-3.3%
    30d ago$-1.10-3.3%
    7d ago$-1.08-1.0%
    Current$-1.07
    Revenue Consensus
    $0
    Range$0 - $0
    17 analysts
    Dec 31, 2026
    EPS Consensus$-1.42
    Range$-2.17 - $-0.63
    16 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    18 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.42---
    Sep 26EST
    		-$-1.07---
    Jun 26
    		$-1.10$-1.21+9.09%Beat-89.7%
    Mar 26
    		$-1.37$-0.91-50.55%Miss-234.1%
    Dec 25
    		$-1.38$-0.90-53.33%Miss-331.2%
    Sep 25
    		$-0.81$-0.67-20.90%Miss-268.2%
    Jun 25
    		$-0.58$-0.44-31.82%Miss-190.0%
    Mar 25
    		$-0.41$-0.31-32.26%Miss-57.7%
    Dec 24
    		$-0.32$-0.27-18.52%Miss-28.0%
    Sep 24
    		$-0.22$-0.24+8.33%Beat+4.3%
    Jun 24
    		$-0.20$-0.27+25.93%Beat-5.3%
    Mar 24
    		$-0.26$-0.28+7.14%Beat-4.0%
    Dec 23
    		$-0.25$-0.25+0.00%Beat+3.8%
    Sep 23
    		$-0.23$-0.22-4.55%Miss-9.5%
    Jun 23
    		$-0.19$-0.20+5.00%Beat+17.4%
    Mar 23
    		$-0.25$-0.24-4.17%Miss-19.0%
    Dec 22
    		$-0.26$-0.23-13.04%Miss-62.5%
    Sep 22
    		$-0.21$-0.23+8.70%Beat-23.5%
    Jun 22
    		$-0.23$-0.21-9.52%Miss-15.0%
    Mar 22
    		$-0.21$-0.19-10.53%Miss-10.5%
    Dec 21
    		$-0.16$-0.19+15.79%Beat-6.7%
    Sep 21
    		$-0.17$-0.21+19.05%Beat-30.8%
    Jun 21
    		$-0.20$-0.20+0.00%Beat-53.8%
    Mar 21
    		$-0.19$-0.17-11.76%Miss-46.2%
    Dec 20
    		$-0.15$-0.15+0.00%Beat-50.0%
    Sep 20
    		$-0.13$-0.15+13.33%Beat-62.5%
    Jun 20
    		$-0.13$-0.14+7.14%Beat-18.2%
    Mar 20
    		$-0.13$-0.12-8.33%Miss-85.7%
    Dec 19
    		$-0.10$-0.13+23.08%Beat-42.9%
    Sep 19
    		$-0.08$-0.12+33.33%Beat+27.3%
    Jun 19
    		$-0.11$-0.09-22.22%Miss+15.4%
    Mar 19
    		$-0.07$-0.09+22.22%Beat+12.5%
    Dec 18
    		$-0.07$-0.10+30.00%Beat+50.0%
    Sep 18
    		$-0.11$-0.11+0.00%Beat+50.0%
    Jun 18
    		$-0.13$-0.12-8.33%Miss+38.1%
    Mar 18
    		$-0.08$-0.12+33.33%Beat+65.2%
    Dec 17
    		$-0.14$-0.17+17.65%Beat+22.2%
    Sep 17
    		$-0.22$-0.20-10.00%Miss-10.0%
    Jun 17
    		$-0.21$-0.19-10.53%Miss-
    Mar 17
    		$-0.23$-0.18-27.78%Miss-
    Dec 16
    		$-0.18$-0.20+10.00%Beat-
    Sep 16
    		$-0.20$-0.23+13.04%Beat-

    Key Metrics

    Valuation
    P/E Ratio-7.03EV/EBITDA-71.64x
    Price/FCF-9.11xFCF Yield-10.98%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-88.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.72xQuick Ratio4.72x
    Trading Statistics
    Beta0.69Avg Volume1.75M
    52-Week High$43.1552-Week Low$22.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$33.82
    SMA 20$33.71
    SMA 50$35.55
    SMA 200$33.61
    EMA 10$33.50
    EMA 20$33.83
    EMA 50$34.12
    EMA 200$33.16

    MACD

    Line: -0.40Signal: -0.34Hist: -0.06

    ADX

    ADX: 15.5+DI: 18.1-DI: 24.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$35.82

    Bollinger Bands

    Upper Band$35.33
    Lower Band$32.09
    %B Position963%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    44.3

    Momentum Oscillators

    Stoch %K22.2
    Stoch %D33.3
    Williams %R-76.3
    ROC (10d)-2.5%
    Momentum-0.85
    CCI (20d)-142.3
    MFI (14d)33.6

    Volatility Measures

    ATR (14d)$1.53(4.7%)
    StdDev (20d)0.81
    Hist Vol45.6%(High)

    Volume Flow

    VWAP$32.48
    OBV31.2M
    AD Line2.4M
    CMF (20d)-0.003

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.9x
    VWMA (20d)$33.70

    Pivot Points

    R3$35.23
    R2$34.55
    R1$33.35
    Pivot Point$32.67
    S1$31.47
    S2$30.79
    S3$29.59

    Advanced Oscillators

    TSI-7.07
    Ultimate Osc47.7
    KST-51.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$436,000$0
    Cost of Revenue$0$0$94,000$0$0$0$110,000$0$0$0$74,000$0
    Gross Profit$0$0$-94,000$0$0$0$-110,000$0$0$0$-74,000$0
    Operating Expenses$132.60M$164.13M$164.75M$98.56M$74.60M$55.49M$46.29M$36.56M$34.07M$34.10M$29.34M$27.27M
    R&D$115.75M$150.15M$153.46M$89.95M$60.15M$41.39M$30.99M$22.79M$23.77M$24.10M$20.50M$18.38M
    SG&A$16.84M$13.97M$11.28M$8.61M$14.42M$14.08M$15.25M$13.77M$10.29M$9.97M$8.78M$8.89M
    Operating Income$-132,597,000$-164,125,000$-164,738,000$-98,561,000$-74,574,000$-55,469,000$-46,238,000$-36,556,000$-34,054,000$-34,073,000$-29,285,000$-27,265,000
    Interest Income$4.54M$5.80M$7.04M$7.77M$9.03M$9.86M$10.84M$11.53M$11.82M$6.75M$4.71M$4.73M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-128,022,000$-158,325,000$-157,650,000$-90,787,000$-65,537,000$-45,605,000$-35,367,000$-24,940,000$-22,234,000$-27,328,000$-24,547,000$-22,532,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-128,022,000$-158,325,000$-157,662,000$-90,787,000$-65,561,000$-45,629,000$-35,417,000$-24,940,000$-22,250,000$-27,356,000$-24,605,000$-22,534,000
    EBITDA$-133,295,000$-165,333,000$-166,375,000$-100,466,000$-76,825,000$-58,467,000$-50,135,000$-41,339,000$-39,397,000$-36,792,000$-31,855,000$-30,335,000
    EBIT$-132,567,000$-164,125,000$-164,738,000$-98,559,000$-74,570,000$-55,469,000$-46,238,000$-36,471,000$-34,054,000$-34,073,000$-29,253,000$-27,265,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VKTX

    News

    Viking Therapeutics Inc (XTER:1VT) Stock Price, Trades & News

    This page provides a comprehensive overview of Viking Therapeutics Inc (XTER:1VT) stock, including its current price, key financial metrics like P/E and P/B ratios, market capitalization, and enterprise value. It also details the company's business description as a biopharmaceutical developer focused on metabolic and endocrine disorders, lists its financial strength, growth, momentum, liquidity, and profitability ranks, and highlights upcoming financial events and recent news releases. The stock is currently trading at €28.3, with a market cap of €3.32B.

    GuruFocus•8/24/26•
    Somewhat-Bearish

    Viking Therapeutics Inc (XTER:1VT) Stock Earnings Transcripts

    This page provides a comprehensive list of earnings call transcripts and conference transcripts for Viking Therapeutics Inc (XTER:1VT) dating back to 2018. It includes transcripts for quarterly earnings calls, presentations at healthcare conferences, and specific trial results calls. Users can access these documents to review the company's historical financial discussions and corporate presentations.

    GuruFocus•8/24/26•
    Neutral

    Viking Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

    This is a transcript of Viking Therapeutics Inc's presentation at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2019. An unidentified company representative discussed the San Diego-based biotech company's portfolio of small molecule drugs, emphasizing their focus on first-in-class or best-in-class therapeutics for metabolic and endocrine disorders, with data from two Phase 2 programs already reported.

    GuruFocus•8/24/26•
    Neutral

    VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress

    Viking Therapeutics (VKTX) shares rose slightly after-hours following updates on its obesity drug programs. The company confirmed that late-stage trials for its injectable obesity drug VK2735 are fully enrolled and progressing as scheduled, with plans for an oral version's late-stage trial by Q4 2026. Despite reporting a net loss of $128 million, investors remain focused on clinical progress as Viking has no approved drug products yet.

    Stocktwits•8/21/26•
    Neutral

    Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research

    Zacks Research has upgraded Viking Therapeutics (NASDAQ:VKTX) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a target price of $96.62. The company's stock rose 7.8% on Tuesday after exceeding quarterly loss expectations. Despite recent insider stock sales totaling $6.27 million to cover tax obligations, institutional investors hold a significant 76.03% stake in Viking Therapeutics.

    MarketBeat•8/20/26•
    Neutral

    Frequently Asked Questions About VKTX

    Does VKTX pay dividends?
    Viking Therapeutics Inc (VKTX) does not currently pay a regular dividend.
    What is VKTX's market cap?
    Viking Therapeutics Inc (VKTX) has a market capitalization of $3.75B with a current stock price of $32.78.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In